Shots:

• Nestle to acquire all outstanding shares of Aimmune’s common stock for $34.50/share in cash- making a total deal value as $2.6B- representing a 174% premium to Aimmune's closing share price on Aug 28- 2020- of $12.60. The transaction is expected to close in Q4’20
• The acquisition extends Nestle’s food allergy portfolio with the addition of Palforzia- creating a broader spectrum of solutions for children living with food allergies
• Aimmune's Palforzia is the first and only FDA-approved treatment- which helps in reducing the frequency and severity of the allergic reaction to peanuts- including anaphylaxis- in children aged 4-17yrs.

­ Ref: Aimmune | Image: Aimmune